1%), and baseline eGFR (86.4% unimpaired). There was no significant difference in the proportion of patients

reclassified FK506 purchase to a more severe renal function classification (Figure ) or in the proportion of patients who experienced a decrease in eGFR of ≥ 20% in those exposed to TDF vs. controls. The incidence density for reclassification to a more severe renal impairment was 7.4 cases/100 patient-years for TDF vs. 11.5 for controls. The relative risk of TDF to controls was 0.64 (95% CI = 0.31-1.34). On multivariate analysis also inclusive of sex, cirrhosis, HTN and DM, significant independent predictors for more severe renal impairment was age (HR = 1.13, 95% CI = 1.07-1.20) and mild baseline renal impairment (HR=10.8, 95% CI = 1.75-66.4), but not TDF exposure. Similar findings were found for predictors for decrease in eGFR ≥ 20%. Conclusions: TDF treatment was not an independent Acalabrutinib in vitro predictor for significant deterioration of renal function. Renal function of HBV patients on antiviral therapy should be monitored, especially in older patients with pre-existing renal dysfunction. Cumulative incidence of patients reclassified to a lower estimated glomerular filtration rate in the tenofovir group (TDF) and control groups (in months).

Disclosures: Huy N. Trinh – Advisory Committees or Review Panels: BMS, Gilead; Grant/ Research Support: BMS, Gilead; Speaking and Teaching: BMS, Gilead, vertex; Stock Shareholder: Gilead Mindie H. Nguyen – Advisory Committees or Review Panels: Bristol-Myers Squibb, Bayer AG, Gilead, Novartis, Onyx; Consulting: Gilead Sciences, Inc.; Grant/Research Support: Gilead Sciences, Inc., Bristol-Myers Squibb, Novartis Pharmaceuticals, Roche Pharma MCE公司 AG, Idenix, Hologic, ISIS The following people have nothing to disclose: Nghi

B. Ha, Kevin Ku, Nghiem B. Ha, Kevin T. Chaung [Objectives] A sustained reduction in HBV DNA and alanine aminotransferase (ALT) levels and the elimination of hepatitis B surface antigen (HBsAg) are important to suppress chronic hepatitis B-induced liver carcinogenesis. We previously reported that in patients receiving long-term nucleoside analog (NA) therapy, HBsAg levels contributed to hepatocellular carcinoma (Kawanaka M et al. Liver Cancer 2014; 3: 41-52). However, long-term NA therapy is less likely to decrease HBsAg levels. Therefore, we administered sequential therapy with pegylated interferon alfa-2a (Peg-IFN alfa-2a) in patients who underwent long-term NA therapy and examined its ability to decrease HBsAg levels and render the patients drug-free. [Methods] Fourteen patients (mean age, 51 [37-63] years; M/F: 12/2; genotype C: 13 patients) who were treated with NA for ≥2 years (mean, 6.6 years) that resulted in HBV DNA levels ≤2.1 Log IU/mL, ALT level normalization, and HBeAg negativity. Sequential therapy of Peg-IFN alfa-2a was conducted for 48 weeks and the capacity of the treatment to decrease ALT levels, HBsAg loss, and the patients drug free was examined.